Publications by authors named "Gerd Burmester"

Claim this Profile
C
Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör

Rheumatol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
Gerd R Burmester, Atul Deodhar, Alan D Irvine, Remo Panaccione, Kevin L Winthrop

Adv Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.
Andreas Hess, Koray Tascilar, Hanna M Schenker, Laura Konerth, Verena Schönau, Gerd R Burmester

Lancet Rheumatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Gerd Burmester, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska

Clin Drug Investig· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI).
Nele Stumper, Jörn Berger, Jens Klotsche, Egbert Gedat, Paula Hoff, Gerd R Burmester

RMD Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.
Gerd R Burmester, Eduardo Mysler, Peter Taylor, Stephen Hall, Bettina Wick-Urban

RMD Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, Daniel Aletaha, Johan Askling, Gerd R Burmester

Ann Rheum Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler, Janusz Jaworski, SungHyun Kim

Expert Rev Clin Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid factors revisited in the age of biologic therapy.
Ali Berkant Avci, Eugen Feist, Gerd R Burmester

Rheumatology (Oxford)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
Miwa Haranaka, Takashi Eto, Takanori Tanaka, Rie Yazawa, Gerd Burmester

J Clin Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
Kenneth Frank Baker, Julia Spierings, Martin Brom, Timothy Radstake, Emma Smith, Gerd R Burmester

Ann Rheum Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Gerd R Burmester

Ann Rheum Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Bayram Farisogullari, Saskia Lawson-Tovey, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Gerd R Burmester

Ann Rheum Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Head-to-head studies in rheumatology].
Gerd R Burmester, Frank Behrens

Z Rheumatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Gerd R Burmester

RMD Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving organisation to improve care: ERN ReCONNET organisational reference model for systemic sclerosis patients' care pathway.
Rosaria Talarico, Diana Marinello, Ilaria Palla, Sara Cannizzo, Ilaria Galetti, Gerd Burmester

J Scleroderma Relat Disord· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
Gerd R Burmester, Jacques-Eric Gottenberg, Roberto Caporali, Kevin L Winthrop, Yoshiya Tanaka

Ann Rheum Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu

J Rheumatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, MinKyu Park, JunGi Hwang, Gerd R Burmester

Expert Opin Biol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Gerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F Azevedo

Rheumatol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding ultrasound to treat-to-target shows no benefit in achieving clinical remission nor in slowing radiographic progression in rheumatoid arthritis: results from a multicenter prospective cohort.
Alexandre Sepriano, Sofia Ramiro, Robert Landewé, Désirée van der Heijde, Sarah Ohrndorf, Gerd Burmester

Clin Rheumatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Gerd R Burmester

Ann Rheum Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis.
Jeffrey A Sparks, Philippe Dieudé, Anna-Maria Hoffmann-Vold, Gerd R Burmester, Simon Lf Walsh

BMC Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
Juergen Rech, Koray Tascilar, Melanie Hagen, Arnd Kleyer, Bernhard Manger, Gerd R Burmester

Lancet· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obexelimab in IgG4-related disease: B-cell inhibition as a novel therapeutic approach.
Tobias Alexander, Gerd R Burmester

Lancet Rheumatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis